TNXP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
17.2M
+27.2%
13.5M
+96.9%
6.9M
+27.6%
5.4M
+63.8%
3.3M
Cost of Revenue
1.3M
+78.1%
703.0K
-55.4%
1.6M
+49.1%
1.1M
-22.6%
1.4M
Gross Profit
16.0M
+24.5%
12.8M
+142.3%
5.3M
+22.3%
4.3M
+125.3%
1.9M
Operating Expenses
71.4M
+29.0%
55.4M
+18.2%
46.8M
-11.0%
52.6M
+50.4%
35.0M
R&D
25.8M
+33.0%
19.4M
+6.6%
18.2M
+7.5%
16.9M
+82.4%
9.3M
SG&A
45.6M
+26.8%
36.0M
+25.6%
28.6M
-19.8%
35.7M
+38.8%
25.7M
Operating Income
-55432000
-30.3%
-42535000
-2.4%
-41537000
+14.0%
-48286000
-46.0%
-33067000
EBITDA
-54789000
-30.7%
-41916000
-2.3%
-40982000
+14.3%
-47798000
-46.6%
-32606000
Net Income
-53329000
-31.5%
-40552000
-0.9%
-40194000
+14.3%
-46910000
-46.5%
-32010000
EPS (Basic)
$-2.89
-18.4%
$-2.44
+16.7%
$-2.93
+25.8%
$-3.95
-10.0%
$-3.59
EPS (Diluted)
$-2.89
-18.4%
$-2.44
+16.7%
$-2.93
+25.8%
$-3.95
-10.0%
$-3.59
Shares (Diluted)
18.4M
+10.9%
16.6M
+21.4%
13.7M
+15.5%
11.9M
+33.0%
8.9M
Tonix Pharmaceuticals (TNXP) — Financials